EDIT vs LCID · rev $32.3M vs rev $1.35B
Editas Medicine Inc (EDIT) versus Lucid Group Inc (LCID) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Lucid Group Inc (LCID) is a auto manufacturers company listed on NASDAQ. It is led by Peter Rawlinson.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported LCID revenue for 2025-12-31 was $1.35B. Net income was -$2.70B. Revenue was up 67.6% from 2024-12-31 to 2025-12-31. LCID currently screens at market cap $2.04B.
EDIT currently screens at market cap $375.2M. LCID currently screens at market cap $2.04B.
Not investment advice. Open the EDIT and LCID stock pages for the full models.
Not investment advice.